Skip Navigation

Details for High Impact Journal

Maintenance notice: We are currently addressing issues with broken links due to recent major website changes. We apologize for any inconvenience and appreciate your patience. Please contact brittany.trottier@niehs.nih.gov for assistance.

Superfund Research Program

Hepatology (Baltimore, Md.) (impact factor: 17.425)

2021

  • Dhar D, Loomba R. 2021. Emerging metabolic and transcriptomic signature of PNPLA3-Associated NASH. Hepatology 73:PMID:33544416
  • Hagstrom H, Adams LA, Allen AM, Byrne CD, Chang Y, Gronbaek H, Ismail M, Kanwal F, Kramer J, Lazarus JV, Long MT, Loomba R, Newsome PN, Rowe IA, Ryu S, Schattenberg JM, Serper M, Sheron N, Simon TG, Tapper EB, Wild S, Wong VW, Yilmaz Y, Zelber-Sagi S, Aberg F. 2021. Administrative coding in electronic health care record-based research of NAFLD: An expert panel consensus statement. Hepatology 74:474-482. doi:10.1002/hep.31726 PMID:33486773 PMCID:PMC8515502
  • Loomba R. 2021. MRI-proton density fat fraction treatment response criteria in nonalcoholic steatohepatitis. Hepatology 73:881-883. doi:10.1002/hep.31624 PMID:33179266 PMCID:PMC8221026
  • Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. 2021. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology 73:126-143. doi:10.1002/hep.31523 PMID:32794259 PMCID:PMC7898628
  • Rosenthal SB, Liu X, Ganguly S, Dhar D, Pasillas M, Ricciardelli E, Li RZ, Troutman T, Kisseleva T, Glass CK, Brenner DA. 2021. Heterogeneity of HSCs in a mouse model of NASH. Hepatology 74(2):667-685. doi:10.1002/hep.31743 PMID:33550587 PMCID:PMC8346581
  • Rusyn I, Arzuaga X, Cattley RC, Corton JC, Ferguson SS, Godoy P, Guyton KZ, Kaplowitz N, Khetani SR, Roberts RA, Roth RA, Smith MT. 2021. Key characteristics of human hepatotoxicants as a basis for identification and characterization of the causes of liver toxicity. Hepatology 74(6):doi:10.1002/hep.31999 PMID:34105804 (ahead of print)
  • Tamaki N, Imajo K, Sharpton S, Jung J, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. 2021. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. Hepatology 75(3):doi:10.1002/hep.32145 PMID:34496054
  • Vilarinho S, Ajmera VH, Zheng M, Loomba R. 2021. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD. Hepatology 74(4):doi:10.1002/hep.32047 PMID:34233030 PMCID:PMC8463418

2020

  • Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, Zamani A, Lopez S, Mangla N, Bettencourt R, Rizo E, Valasek MA, Behling C, Richards L, Sirlin C, Loomba R. 2020. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology 71(3):849-860. doi:10.1002/hep.30974 PMID:31556124 PMCID:PMC7828573
  • Cave MC. 2020. Environmental Pollution and the Developmental Origins of Childhood Liver Disease. Hepatology 72:1518-1521. doi:10.1002/hep.31549 PMID:32910501
  • Stender S, Loomba R. 2020. PNPLA3 genotype and risk of liver and all-cause mortality. Hepatology 71:777-779. doi:10.1002/hep.31113 PMID:31954067
  • Verna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia-Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. 2020. Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. Hepatology 72:1819-1837. doi:10.1002/hep.31491 PMID:32740969 PMCID:PMC7435542

2019

  • Caussy C, Bhargava M, Villesen I, Gudmann N, Leeming D, Karsdal M, Faulkner C, Bao D, Liu A, Lo M, Bettencourt R, Bassirian S, Richards L, Brenner DA, Chen C, Sirlin C, Loomba R. 2019. Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. Hepatology 70(1):127-141. doi:10.1002/hep.30610 PMID:30859582 PMCID:PMC6984974
  • Liu P, de la Vega MR, Dodson M, Yue F, Shi B, Fang D, Chapman E, Liu L, Zhang DD. 2019. Spermidine confers liver protection by enhancing NRF2 signaling through a MAP1S-mediated noncanonical mechanism. Hepatology 70(1):372-388. doi:10.1002/hep.30616 PMID:30873635 PMCID:PMC6597327
  • Loomba R, Adams L. 2019. The 20 Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH. Hepatology 70(6):1885-1888. doi:10.1002/hep.30946 PMID:31520407 PMCID:PMC7504908

2018

  • Brenner DA. 2018. Of Mice and Men and Nonalcoholic Steatohepatitis. Hepatology 68(6):2059-2061. doi:10.1002/hep.30186 PMID:30033687 PMCID:PMC6398944
  • Caussy C, Hsu CL, Lo M, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen C, Loomba R. 2018. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology 68(3):918-932. doi:10.1002/hep.29892 PMID:29572891 PMCID:PMC6151296
  • Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Starkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. 2018. Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice. Hepatology doi:10.1002/hep.29676 PMID:29159825 PMCID:PMC5962369
  • Tapper EB, Loomba R. 2018. Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists. Hepatology 67:1657-1659. doi:10.1002/hep.29722 PMID:29222913 PMCID:PMC5906195

2017

  • Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R. 2017. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557-1565. doi:10.1002/hep.29085 PMID:28130788 PMCID:PMC5397356

2016

  • Cui J, Chen C, Lo M, Schork N, Bettencourt R, Gonzalez MP, Bhatt A, Hooker J, Shaffer K, Nelson KE, Long MT, Brenner DA, Sirlin CB, Loomba R. 2016. Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. Hepatology 64(5):1547-1558. doi:10.1002/hep.28674 PMID:27315352 PMCID:PMC5090982
  • Hsin I, Montano E, Seki E. 2016. Finding a new role for NEMO: a key player in preventing hepatocyte apoptosis and liver tumorigenesis by inhibiting RIPK1. Hepatology 64(1):295-297. doi:10.1002/hep.28627 PMID:27122117 PMCID:PMC4917439
  • Seki E. 2016. HEDGEHOG Signal in hepatocytes mediates macrophage recruitment: a new mechanism and potential therapeutic target for fatty liver disease. Hepatology 63(4):1071-1073. doi:10.1002/hep.28381 PMID:26638191 PMCID:PMC4805480

2015

2014

  • Roh Y, Park S, Kim J, Lim C, Seki E, Kim B. 2014. Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis. Hepatology 60(1):237-249. doi:10.1002/hep.26981 PMID:24375615 PMCID:PMC4273749

2012

2007

  • Bonzo JA, Belanger A, Tukey RH. 2007. The role of chrysin and the Ah receptor in induction of the human UGT1A1 gene in vitro and in transgenic UGT1 mice. Hepatology 45(2):349-360. PMID:17256720
  • Straub AC, Stolz DB, Ross MA, Hernandez-Zavala A, Soucy NV, Klei LR, Barchowsky A. 2007. Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver. Hepatology 45(1):205-12. PMID:17187425

2004

  • Khetani SR, Szulgit G, Del Rio JA, Barlow C, Bhatia SN. 2004. Exploring interactions between rat hepatocytes and nonparenchymal cells using gene expression profiling. Hepatology 40(3):545-554. doi:10.1002/hep.20351 PMID:15349892

2002

  • Yin L, Sun M, Ilic Z, Leffert HL, Sell S. 2002. Derivation, characterization, and phenotypic variation of hepatic progenitor cell lines isolated from adult rats. Hepatology 35(2):315-324. PMID:11826404

2001

  • Allen JW, Hassanein T, Bhatia SN. 2001. Advances in bioartificial liver devices. Hepatology 34(3):447-455. PMID:11526528

1996

  • Wagner JG, Ganey PE, Roth RA. 1996. Nitric oxide is not involved in hepatocyte killing by neutrophils activated by N-formyl-methionyl-leucyl-phenylalanine or phorbol myristate acetate in vitro. Hepatology 23(4):803-810. PMID:8666335

1995

  • Chiao C, Zhang Y, Kaufman DG, Kaufmann WK. 1995. Phenobarbital modulates the type of cell death by initiated hepatocytes during deprivation of serum in vitro. Hepatology 22(1):297-303. PMID:7601424
Back
to Top